Maria Blaszkowska

Maria Blaszkowska

Auto-generated profile, based on publicly available information

Maria Blaszkowska

Department of Clinical Oncology, No. 4 Provincial Specialist Hospital, 41-902 Bytom, Poland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
JJJerzy Jaroszewicz
Jerzy Jaroszewicz
IBIwona Buczyńska
Iwona Buczyńska
KSKrzysztof Simon
Krzysztof Simon
BLBeata Lorenc
Beata Lorenc
RFRobert Flisiak
Robert Flisiak

11 March 2020 in Neurological Research
Verified
Journal Article
Closed access
NNNatalia Anna Niedziela
Natalia Anna Niedziela
MNMaria Nowak-Kiczmer
Maria Nowak-Kiczmer
MLMartyna Lis
Martyna Lis
MDMaria Dąbrowska
Maria Dąbrowska
RKRozalia Kośmider
Rozalia Kośmider
MAMonika Adamczyk-Sowa
Monika Adamczyk-Sowa
Objective: To determine the time of dementia diagnosis, symptom intensity and to assess the comorbidities. Methods: 110 patients with dementia or mild cognitive impairment were enrolled in this retrospective study. The study group was divided into subgroups: patients with a maximum of three (S ≤ 3 n = 62) and four or more symptoms (S ≥ 4 n = 48). Baseline characteristics, disease duration and the number of comorbidities were analyzed. Results: The median time from the first symptoms to diagnosis [months] (FS-D) was 12.0, while from diagnosis to enrollment (D-E) was 42.66. The median time from D-E was significantly longer in S ≥ 4 and significant correlation was observed between the median time from D-E and number of symptoms [n] (R = 0.3240, p < 0.05). Significantly more patients were newly diagnosed with AF [%] [14.58 vs. 3.23, p = 0.032], Parkinson’s disease [29.17 vs. 8.06, p = 0.004] and depression [31.25 vs. 6.45, p = 0.001] in S ≥ 4 compared to S ≤ 3, respectively. Conclusions: A considerable delay in the diagnosis of dementia was confirmed. Clinical features were associated with the disease duration and the severity of symptoms. Appropriate diagnosis of AF in patients with dementia is of great importance.

1 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
PPPaweł Michał Potocki
Paweł Michał Potocki
RWRafał Maciej Wiśniowski
Rafał Maciej Wiśniowski
DHDominik Haus
Dominik Haus
ZCZbyszko Chowaniec
Zbyszko Chowaniec
MKMaciej Kozaczka
Maciej Kozaczka
Piotr J. WysockiPiotr J. Wysocki
Piotr J. Wysocki
Anti-EGFR antibodies combined with chemotherapy doublets are a cornerstone of the upfront treatment of colorectal cancer. RAS and BRAF mutations are established negative predictive factors for such therapy. The primary tumour located in the proximal colon has recently emerged as another negative predictive factor. We have conducted a retrospective multicentre study to collect data on real-world population characteristics, practice patterns, and outcomes in patients with metastatic colorectal cancer treated in a first-line setting with either cetuximab or panitumumab in combination with either FOLFOX or FOLFIRI chemotherapy. The presented analysis focuses on the impact of the primary tumour location. 126 of 842 patients analysed (15.0%) had proximal primary. It was associated with a lower BMI at diagnosis, mucinous histology, and peritoneal metastases. It was also associated with inferior treatment outcomes in terms of response ratio: 59.4% vs. 74.22% (odds ratio [OR] 0.51, 95% CI 0.33–0.78, p = 0.010), and median depth of response: −36.7% vs. −50.0% (p = 0.038). There was only a borderline non-significant trend for inferior PFS in patients with proximal tumours. OS data was incomplete. The presented analysis confirms the negative impact of tumour sidedness on the efficacy of an upfront anti-EGFR-chemotherapy combination and provides valuable data on real-world population characteristics.

Verified
Journal Article
Open access
PDF file
AKAgnieszka Kalita
Agnieszka Kalita
MSMagdalena Sikora-Skrabaka
Magdalena Sikora-Skrabaka
KGKarolina Gołąbek
Karolina Gołąbek
MDMaria Dąbrowska
Maria Dąbrowska
Joanna Katarzyna StrzelczykJoanna Katarzyna Strzelczyk
Joanna Katarzyna Strzelczyk
ENEwa Maria Nowakowska-Zajdel
Ewa Maria Nowakowska-Zajdel
The role of adamalysins (ADAMs) has been widely described in many processes related to carcinogenesis, angiogenesis, inflammation, metastasis, and metabolic disorders. Despite numerous studies, their role in colorectal cancer (CRC) remains unclear. The aim of this study was to evaluate the expression of selected ADAM genes in colorectal cancer tissue and corresponding surgical margins. In addition, for a subgroup of patients, the expression of selected proteins from the ADAM family was assessed. The final study group consisted of 67 patients who underwent elective surgery for colorectal cancer. The relative expression of the ADAM10, 12, 17, and 28 genes was expressed as relative quantification (RQ) and determined by real-time quantitative PCR (RT-qPCR) in tumor tissue and surgical margins. In addition, for a subgroup of 45 patients, the expression of ADAM10, 12, and 17 proteins was assessed by ELISA. Associations between ADAM expression and clinicopathological parameters were analyzed statistically. ADAM12 gene expression was significantly higher in tumor than in margin tissue (median RQ: 0.995 vs. 0.251; p = 0.003), whereas ADAM28 RQ was significantly higher in the margin (median RQ: 0.400 vs. 0.204; p = 0.021). No significant differences were observed in the expression of the ADAM10, ADAM12, ADAM17, or ADAM28 genes based on tumor stage, sex, substance use, BMI, or age, except for nominally higher ADAM12 gene expression in patients over 65 years of age (p = 0.033). Among patients under 65 years of age with cardiovascular disease (CVD), ADAM28 RQ in tumor tissue was significantly higher than in those without CVD (p < 0.05). In obese patients with CVD, a markedly increased expression of ADAM28 in tumor tissue was observed, regardless of age (1.469 vs. 0.132; p < 0.005). Significant positive correlations were observed between the ADAM10 and ADAM17 RQ, and between the ADAM10 and ADAM28 RQ, in both tumor and marginal tissues (all adjusted p < 0.01). No significant correlations were found between gene expression and corresponding protein levels for ADAM10, ADAM12, or ADAM17. ADAM10, 12, 17, and 28 are poor biomarkers for colorectal cancer, but their significance may increase in patients with comorbid metabolic disorders. The lack of correlation between protein expression and gene expression suggests the contribution of post-transcriptional and post-translational regulatory mechanisms, which justifies further research.